Skip to main content

Table 4 Prognostic role of TILs and ICs in elderly HNSCC patients undergoing (chemo)radiotherapy

From: Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy

 

OS

PFS

LRF

Variable

HR

CI 95%

p

HR

CI 95%

p

SHR

CI 95%

p

HPV (reference: HPV-negative)

0.48

0.19–1.23

0.13

0.43

0.17–1.09

0.08

 < 0.001

 < 0.001- < 0.001

 < 0.001

Localization (reference: non-oropharynx)

0.36

0.18–0.72

 < 0.01

0.37

0.19–0.73

 < 0.01

0.36

0.10–1.27

0.11

CD3 + TILs (intraepithelial)

0.99

0.58–1.70

0.98

0.88

0.53–1.46

0.62

0.52

0.26–1.06

0.07

CD3 + TILs (stromal)

1.06

0.45–2.52

0.90

0.69

0.32–1.50

0.35

0.41

0.14–1.23

0.11

CD4 + TILs (intraepithelial)

1.20

0.66–2.16

0.55

0.99

0.55–1.76

0.96

0.57

0.17–1.92

0.37

CD4 + TILs (stromal)

0.89

0.59–1.36

0.60

0.80

0.53–1.22

0.31

0.53

0.24–1.17

0.12

CD8 + TILs (intraepithelial)

1.12

0.71–1.75

0.63

0.93

0.60–1.44

0.73

0.52

0.25–1.10

0.09

CD8 + TILs (stromal)

1.53

0.83–2.85

0.18

1.27

0.69–2.31

0.45

0.67

0.22–1.98

0.47

TPS (continuous)

1.39

0.34–5.73

0.65

1.01

0.25–4.11

0.99

0.96

0.90–1.03

0.22

TPS (reference: TPS = 0)

1.03

0.55–1.93

0.94

0.81

0.44–1.50

0.51

0.28

0.09–0.93

 < 0.05

CPS (continuous)

1.00

0.99–1.02

0.87

1.00

0.98–1.01

0.79

0.94

0.88–1.01

0.08

CPS (reference: CPS = 0)

0.97

0.51–1.83

0.92

0.85

0.46–1.58

0.61

0.34

0.11–1.01

0.05

TIM3 (intraepithelial)

1.06

0.64–1.75

0.84

0.95

0.57–1.58

0.84

0.42

0.15–1.18

0.10

TIM3 (stromal)

0.81

0.46–1.43

0.47

0.72

0.41–1.27

0.26

0.32

0.14–0.76

 < 0.05

LAG3 (intraepithelial)

1.16

0.70–1.90

0.57

0.96

0.58–1.58

0.87

0.33

0.12–0.93

 < 0.05

LAG3 (stromal)

0.71

0.41–1.24

0.23

0.68

0.40–1.16

0.15

0.38

0.15–0.95

 < 0.05

TIGIT (intraepithelial)

1.12

0.74–1.70

0.60

1.05

0.68–1.61

0.84

0.62

0.27–1.39

0.25

TIGIT (stromal)

1.31

0.77–2.24

0.32

1.10

0.66–1.83

0.72

0.54

0.25–1.16

0.11

CD96 (intraepithelial)

1.96

0.81–4.74

0.14

1.49

0.63–3.56

0.37

0.57

0.07–4.49

0.60

CD96 (stromal)

0.98

0.54–1.80

0.95

0.79

0.44–1.42

0.43

1.00

0.40–2.52

0.99

Osteopontina (continuous)

1.00

0.99–1.00

0.48

1.00

0.99–1.00

0.32

1.00

0.98–1.01

0.53

  1. Bold indicate p-values < 0.05
  2. Cox proportional hazard regression analyses were performed regarding OS and PFS, while the Fine and Gray's proportional subhazards model was used for LRF analyses considering the presence of competing risks
  3. a Osteopontin H score
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us